$PHIO News

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance

Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026

Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference

Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference

Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

HC Wainwright & Co. Reiterates Buy on Phio Pharmaceuticals, Maintains $14 Price Target

Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894

Phio Pharmaceuticals Receives US Notice Of Allowance For Patent Covering PH-894, Further Strengthening Company's IP Portfolio

Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

Phio Pharmaceuticals Expands Global Patent Portfolio With New International Patent Milestones

Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision

Phio Pharmaceuticals Announces Multiple Favorable Patent Actions Encompassing Three Notices Of Allowance And One Grant Decision

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026

Phio Pharma To Discuss siRNA Oncology At Force Family Office Fireside Chat; INTASYL Program Positioned As Differentiated Immuno‑Oncology Strategy

Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762